Kana Kurokawa Munechika Hara Shin-Ichiro Iwakami Takuya Genda Naoko Iwakami Yosuke Miyashita Masahiro Fujioka Shinichi Sasaki Kazuhisa Takahashi
10.2169/internalmedicine.2591-18
Intern Med
2019;58(22):3283-3287.
cholestatic liver injury hepatotoxicity immune checkpoint inhibitor ursodeoxycholic acid
CC BY-NC-ND
https://pubmed.ncbi.nlm.nih.gov/31735738/
Adenocarcinoma of Lung / drug therapy Antibodies, Monoclonal, Humanized / adverse effects Antibodies, Monoclonal, Humanized / therapeutic use Antineoplastic Agents, Immunological / adverse effects Antineoplastic Agents, Immunological / therapeutic use Cholestasis / chemically induced Lung Neoplasms / drug therapy
Adenocarcinoma of Lung / drug therapy Antibodies, Monoclonal, Humanized / adverse effects Antibodies, Monoclonal, Humanized / therapeutic use Antineoplastic Agents, Immunological / adverse effects Antineoplastic Agents, Immunological / therapeutic use Cholestasis / chemically induced Lung Neoplasms / drug therapy Case Reports Cholestasis / drug therapy Humans Male Middle Aged Treatment Outcome Ursodeoxycholic Acid / therapeutic use Antibodies, Monoclonal, Humanized Antineoplastic Agents, Immunological Ursodeoxycholic Acid pembrolizumab
PMC6911765
31735738
Cholestatic Liver Injury Induced by Pembrolizumab in a Patient with Lung Adenocarcinoma
2019